| Management target | Revenue 18.0% Next 3-4 Years |
|---|
| Margins | Standalone EBITDA margins stable at ~23% despite derivative impacts. |
|---|---|
| Demand visibility | Xanthine capacity enhanced to 5,000 TPA; Tarapur Unit 5 adding 3,600 TPA. |
Growth
FY26 Standalone Revenue grew 1.5% YoY; PAT down 31.5% to INR 176 Cr (restated for derivatives).
Outlook
Targeting 15-18% Revenue and EBITDA CAGR over 3-4 years. FY27 CAPEX outlook INR 400 Cr.
Risks
Profitability impacted by long-dated USD forward contract fair value movements; Consolidated revenue decline of 14% YoY.
Investor Presentation filed with NSE, NSE: AARTIPHARM. Summary written with AI assistance from the document.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹939.55
- Market cap
- ₹8,520 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 40.0×Sector 50.4×
- Promoter holding
- 42.86%-0.22% QoQ
- FII holding
- 8.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Promoter Selling: ₹106.4 Cr
Promoters sold a total of 15.12 lakh shares via open market transactions, aggregating to ₹106.43 Crore.
- Value
- ₹106.4 Cr
Aarti Pharmalabs Management Change
Aarti Pharmalabs reported directorate changes, including Shri Rashesh Gogri's appointment as Managing Director, Smt. Hetal Gogri Gala's re-designation, and the cessation of Shri Rajendra Gogri.
Aarti Pharmalabs Promoter Selling
Aarti Pharmalabs promoters sold a net 29.03 lakh shares, reducing their stake from 42.88% to 39.66%. No transaction value is disclosed in this periodic SAST filing.
Aarti Pharmalabs Annual General Meeting
Aarti Pharmalabs conducted its 7th Annual General Meeting on September 22, 2026, to transact ordinary and special business, with voting results to follow.
Aarti Pharmalabs Promoter Selling: ₹10.43 Cr
Promoter Group entities, Safechem Enterprises and Relacion Trusteeship, sold 1,19,400 shares of Aarti Pharmalabs in the open market for a total of ₹10.43 Crore.
- Value
- ₹10.43 Cr
Aarti Pharmalabs Promoter Selling: ₹2.59 Cr
Safechem Enterprises Private Limited, part of the promoter group, sold 30,000 equity shares of Aarti Pharmalabs Ltd in the open market.
- Value
- ₹2.59 Cr
- Promoter stake change
- -0.03%